Tech Guru
Long/short equity, biotech, healthcare, tech

Stemline, Targeting Cancer Stem Cells, Presented Promising Cancer Data At ASCO

Stemline Therapeutics (NASDAQ:STML) is a biopharmaceutical company that is developing cancer therapies targeting cancer stem cells. Stemline presented some exciting results for its lead program SL-104 this weekend at the American Society of Clinical Oncology (OTC:ASCO) meeting in Chicago, validating the company as a strong contender in the cancer stem cell treatment space. The data for lead candidate SL-401 included a response for 5 out of 6 blastic plasmacyoid dendritic cell neoplasm (BPDCN) patients and an increase in overall survival for refractory/relapsed acute myeloid leukemia (AML) patients. SL-401 is a recombinant protein consisting of human interleukin-3 (IL-3), designed to find IL-3 receptors on cancer cells and cancer stem cells, bound to a toxic payload.

A solid...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details